Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations

Lancet Oncology

Volumn 8, Issue 9, 2007, Pages 813-821

  Goonewardene, Tyronne I ^a   Hall, Marcia R ^a   Rustin, Gordon JS ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; AROMATASE INHIBITOR; CA 125 ANTIGEN; CALCITRIOL; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; ISOTRETINOIN; LETROZOLE; MEGESTROL; OXALIPLATIN; PACLITAXEL; TAMOXIFEN; THALIDOMIDE; TOPOTECAN; TUMOR MARKER;

ANTIGEN DETECTION; ANXIETY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL OBSERVATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); DEPRESSION; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; MONOTHERAPY; NEUTROPENIA; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT CARE; PATIENT COUNSELING; PATIENT DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; SYMPTOM; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; CA-125 ANTIGEN; DISEASE PROGRESSION; FEMALE; HUMANS; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 34548161162     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70273-5     Document Type: Review

References (52)

1. Cannistra S. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
2. Bast R., Klug T., and John E. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309 (1983) 883-887
3. Bast R., Feeney M., Lazarus H., Nadler L., Colvin R., and Knapp R. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68 (1981) 1331-1337
4. Yin B., and Lloyd K. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276 (2001) 27371-27375
5. O'Brien T., Beard J., Underwood L., Dennis R., Santin A., and York L. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 22 (2001) 348-366
6. Nustad K., Bast R., Brien T., et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour biol 17 (1996) 196-219
7. Bast R., Xu F., Yu Y., Barnhill S., Zhang Z., and Mills G. CA 125: the past and the future. Int J Biol Markers 13 (1998) 179-187
8. Kenemans P., Verstraeten A., van Kamp G., and von Mensdorff-Pouilly S. The second generation CA 125 assays. Ann Med 27 (1995) 107-113
9. Kabawat S., Bast R., Bhan A., Welch W., Knapp R., and Colvin R. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2 (1983) 275-285
10. Kabawat S. Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 79 (1983) 98-104
11. Nap M. Immunohistochemistry of CA 125. Unusual expression in normal tissues, distribution in the human fetus and questions around its application in diagnostic pathology. Int J Biol Markers 13 (1998) 210-215
12. Grover S., Koh H., Weideman P., and Quinn M. The effect of the menstrual cycle on serum CA 125 levels: a population study. Am J Obstet Gynecol 167 (1992) 1379-1381
13. Meden H., and Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int J Biol Markers 13 (1998) 231-237
14. Bergmann J., Beaugrand M., Labadie H., Bidart J., and Bohuon C. CA 125 (ovarian tumour-associated antigen) in ascitic liver diseases. Cinic Chimica Acta 155 (1986) 163-165
15. van der Burg M., Lammes F., and Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1 (1990) 301-302
16. Wilder J., Pavlik E., Straughn J., et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol 89 (2003) 233-235
17. Santillan A., Garg R., Zahurak M., et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol 23 (2005) 9338-9343
18. Krebs H., Goplerud D., Kilpatrick S., et al. The role of CA 125 as a tumour marker in ovarian cancer. Obstet Gynecol 67 (1986) 473-477
19. Rustin G., Nelstrop A., Stilwell J., and Lambert H. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer 28 (1992) 79-82
20. Rustin G., Nelstrop A., Tuxen M., and Lambert H. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 7 (1996) 361-364
21. Rustin G., Marples M., Nelstrop A., Mahmoudi M., and Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19 (2001) 4054-4057
22. Therasse P., Arbuck S., Eisenhauer E., et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
23. Piccart M., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92 (2000) 699-708
24. Rustin G., Timmers P., Nelstrop A., et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the Intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 24 (2006) 45-51
25. Blackledge G., Lawton F., Redman C., and Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59 (1989) 650-653
26. Gore M., Fryatt I., Wiltshaw E., and Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynaecol Oncol 36 (1990) 207-211
27. Markman M., Reichman B., Hakes T., et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cance: influence of a prior response to intravenous cisplatin. J Clin Oncol 9 (1991) 1801-1805
28. Eisenhauer E., Vermorken J., and van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8 (1997) 963-968
29. Mayerhofer K., Bodner K., Aktas C., et al. Knowledge of tumor markers and the psychological consequences of tumor marker sampling in patients with gynecologic cancers. Anticancer Res 20 (2000) 1281-1284
30. Harries M., and Gore M. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet 3 (2002) 537-545
31. Parker P., Kudelka A., Basen-Engquist K., Kavanagh J., de Moor J., and Cohen L. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol 100 (2006) 495-500
32. Vergote I., Rustin G., Eisenhauer E., et al. Re: new guidelines to evaluate the response to treatment in solid tumours (ovarian cancer). J Natl Cancer Inst 92 (2000) 1534-1535
33. Zimny M., Siggelkow W., Schroder W., et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 83 (2001) 310-315
34. Bristow R., Giuntoli II R., Pannu H., Schulick R., Fishman E., and Wahl R. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes. Gynecol Oncol 99 (2005) 294-300
35. Bookman M., Malmstrom H., Bollis G., et al. Topetecan for the treatment of advanced epithelial ovarian cancer: and open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16 (1998) 3345-3352
36. Gordon A., Fleagle J., Guthrie D., Parkin D., Gore M., and Lacave A. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19 (2001) 3312-3322
37. Ferrero J., Weber B., Geay J., et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18 (2007) 263-268
38. Rose P., Blessing J., Mayer A., and Homesley H. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynaecologic Oncology Group study. J Clin Oncol 16 (1998) 405-410
39. Rustin G., Nelstrop A., Crawford M., et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol 15 (1997) 172-176
40. Vermorken J., Bokkel Huinink W.t., Kobierska A., et al. Phase 1 study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma. Oncology 57 (1999) 10-16
41. Vermorken J., Kobierska A., van der Burg M., et al. High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience. Eur J Gynaecol Oncol 16 (1995) 433-438
42. Piccart M., Green J., Lacave A., et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomised phase II study of the European Organisation for the Research and Treatment of Cancer Gynaecology Group. J Clin Oncol 18 (2000) 1193-1202
43. Cantu M., Buda A., Parma G., et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20 (2002) 1232-1237
44. Parmar M., Ledermann J., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
45. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An Intergroup Trial of the AGO-OVAR, the NCC CTG, and the EORTC GCG. J Clin Oncol 24 (2006) 4699-4707
46. Hatch K., Beecham J., Blessing J., and Creasman W. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 (1991) 269-271
47. Markman M., Iseminger K., Hatch K., Creasman W., Barnes W., and Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 62 (1996) 4-6
48. Munstedt K., Steen J., Knauf A., Buch T., von Georgi R., and Franke F. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 89 (2000) 1783-1791
49. Wilailak S., Linasmita V., and Srisupundit S. Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer. Anticancer Drugs 12 (2001) 719-724
50. Walker G., Macleod K., Williams A., et al. Insulin-like growth factor binding proteins IGFBP3, IGFBP4 and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 13 (2007) 1438-1444
51. Rustin G., Quinnell T., Johnson J., Clarke H., Nelstrop A., and Bollag W. Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Br J Cancer 74 (1996) 1479-1481
52. Patterson D., Rustin G., Nathan P., et al. Use of changes in CA125 doubling time to detect activity of cytostatic agents in women relapsing with ovarian carcinoma. Study 1-Tamoxifen. Proc Am Soc Clin Oncol 23 (2005) (abstr 5119).